Tempus AI, Inc. announced that its xR assay has received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic device. The certification covers Tempus’ quality management system for “next-generation sequencing devices for cancer genomic profiling to support clinical management.”
xR detects gene rearrangements and specific splice variants in solid tumor tissue to support clinical management. A published study demonstrated that combining Tempus RNA and DNA testing increases detection of clinically actionable gene fusions compared with DNA testing alone.
IVDR certification supports continued access to xR in the EU beyond 2028, the transition deadline for eligible legacy Class C devices, and provides biopharma partners with an IVDR-certified testing platform to support clinical studies.
“Securing our European IVDR certification for xR reinforces our commitment to meeting the highest regulatory standards globally,” said Lauren Silvis, SVP of External Affairs at Tempus. “This achievement establishes a strong regulatory foundation in Europe as we work to expand access to our advanced RNA sequencing tools for healthcare providers, biopharma partners and cancer patients across the region.”
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Source – BusinessWire
Michuda J, Park BH, Cummings AL, Devarakonda S, O’Neil B, Islam S, Parsons J, Ben-Shachar R, Breschi A, Blackwell KL, Chen JL, Dudley J, Stumpe M, Guinney J, Cohen EEW. (2022) Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone. Journal of Clinical Oncology 40(16_suppl): 3077. [article]
Tempus AI, Inc. announced that its xR assay has received certification under the European Union’s In Vitro Diagnostic Regulation (IVDR) as a Class C in vitro diagnostic device. The certification covers Tempus’ quality management system for “next-generation sequencing devices for cancer genomic profiling to support clinical management.”
xR detects gene rearrangements and specific splice variants in solid tumor tissue to support clinical management. A published study demonstrated that combining Tempus RNA and DNA testing increases detection of clinically actionable gene fusions compared with DNA testing alone.
IVDR certification supports continued access to xR in the EU beyond 2028, the transition deadline for eligible legacy Class C devices, and provides biopharma partners with an IVDR-certified testing platform to support clinical studies.
“Securing our European IVDR certification for xR reinforces our commitment to meeting the highest regulatory standards globally,” said Lauren Silvis, SVP of External Affairs at Tempus. “This achievement establishes a strong regulatory foundation in Europe as we work to expand access to our advanced RNA sequencing tools for healthcare providers, biopharma partners and cancer patients across the region.”
About Tempus
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.
Source – BusinessWire
Michuda J, Park BH, Cummings AL, Devarakonda S, O’Neil B, Islam S, Parsons J, Ben-Shachar R, Breschi A, Blackwell KL, Chen JL, Dudley J, Stumpe M, Guinney J, Cohen EEW. (2022) Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone. Journal of Clinical Oncology 40(16_suppl): 3077. [article]











Stay Connected